openPR Logo
Press release

Pneumococcal Vaccine Polyvalent Market Trends, Business Overview, Industry Growth and Forecast to 2028

03-25-2022 06:36 AM CET | Health & Medicine

Press release from: Orion Market Research

The global pneumococcal vaccine polyvalent market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). A polyvalent vaccine is used to prevent infection by the bacterium streptococcus pneumonia. The Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 invasive pneumococcal types of streptococcus pneumonia to ensure cross-protection. According to the data published by World Health Organization (WHO) in 2021, Pneumonia accounted for 14.0% of all mortalities in children in 2019. Further, the WHO states that pneumonia can be protected with simple interventions and can be treated with low cost, low-tech medication, and care. Thus, the pneumococcal vaccines are anticipated to play a significant role in the prevention of pneumonia, which in turn will drive the growth of the global pneumococcal vaccine polyvalent market during the forecast period.

According to the data published by National Center for Biotechnology Information (NCBI), in July 2021, the annual incidence of pneumonia accounted for 24.8 cases per 10,000 adults in the US. However, the rate of incidence is anticipated to rise with the increase in the age of the individual. Moreover, the mortality rate reached 23.0% for the patients admitted to the intensive care unit (ICU). Therefore, the rising incidence of pneumonia across the globe is anticipated to propel the growth of the global pneumococcal vaccine polyvalent market.

Looking towards the demand for pneumococcal vaccine polyvalent key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2021, Merck &Co. had received the US FDA approval of Vaxneuvance for the prevention of invasive pneumococcal disease in adults 18 years and old caused by 15 serotypes. The Vaxneuvance was approved based on data from seven randomized, double-blind clinical studies assessing safety, tolerance, and immunogenicity in adults.

In June 2021, Pfizer Inc. had received the US FDA approval for Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for the prevention of invasive diseases and pneumonia caused by the 20 streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older. In addition, the vaccine also contains capsular polysaccharide conjugates for seven additional serotypes such as 8, 10A, 11a, and more that cause invasive pneumococcal disease (IPD).

Further, in December 2020, the Serum Institute of India has announced the launch of Pneumosil. The drug assists to fight pneumococcal pneumonia amongst children. Pneumonia is developed through a collaboration spanning over a decade among Serum Insititute of India Pvt Ltd, PATH, and Bill and Melinda Gates Foundation. Through this collaboration, the vaccine has advanced from pre-clinical and clinical development to WHO pre-qualification. Therefore, this collaboration aimed at improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low and middle-income countries. Thus, such product launches coupled with product approvals are anticipated to accelerate the growth of global pneumococcal polyvalent vaccine market during the forecast period.

(Get 15% Discount on Buying this Report)
Get Sample Copy of Pneumococcal Vaccine Polyvalent Market at: https://orionmarketreports.com/request-sample/?id=92629&submit=Request+Sample%0D%0A

Market Coverage
•The market number available for - 2021-2028
•Base year- 2021
•Forecast period- 2022-2028
•Segment Covered-
•By Type
•By Age Group
•Regions Covered-
•North America
•Europe
•Asia-Pacific
•Rest of the World

Competitive Landscape- Merck & Co., Inc., GlaxoSmithKline plc, and Pfizer Inc. among others.

A full report Pneumococcal Vaccine Polyvalent Market of is available at:  https://orionmarketreports.com/pneumococcal-vaccine-polyvalent-market/92629/

Global Pneumococcal Vaccine Polyvalent Market Report by Segment
By Type
•Pneumovax 23
•Prevnar 13
By Age Group
•18 years and younger
•19 years to 64 years
•65 years and older

Key questions addressed by the report
•What is the market growth rate?
•Which segment and region dominate the market in the base year?
•Which segment and region will project the fastest growth in the market?
•How has COVID-19 impacted the market?
•Deviation from the pre-COVID-19 forecast
•Most affected region and segment
•Who is the leader in the market?
•How players are addressing challenges to sustain growth?
•Where is the investment opportunity?

 

Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pneumococcal Vaccine Polyvalent Market Trends, Business Overview, Industry Growth and Forecast to 2028 here

News-ID: 2586704 • Views:

More Releases from Orion Market Research

AI-Enabled Imaging Modalities Market Rising Demand and Growth Forecast Through 2033
AI-Enabled Imaging Modalities Market Rising Demand and Growth Forecast Through 2 …
AI-enabled imaging modalities market was valued at approximately USD 1.36 billion, and it is projected to reach around USD 19.78 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 34.67% from 2024 to 2033. AI-Enabled Imaging Modalities Market Overview The AI-enabled imaging modalities market is experiencing rapid growth, driven by advancements in artificial intelligence and machine learning technologies. These innovations are enhancing the capabilities of various imaging modalities, including
Tumor Tracking Systems Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Tumor Tracking Systems Market Size Analysis, Competitive Insights, Leading Playe …
Global tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033. Tumor Tracking Systems Market Overview The tumor tracking systems market is experiencing steady growth, driven by the increasing incidence of cancer and advancements in imaging and tracking technologies. These systems improve the precision of
Tumor Tracking Systems Market Size Future Scope, Demands and Projected Industry Growths to 2033
Tumor Tracking Systems Market Size Future Scope, Demands and Projected Industry …
Tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033. Tumor Tracking Systems Market Overview The tumor tracking systems market is experiencing steady growth, driven by the increasing prevalence of cancer and advancements in imaging technologies. These systems play a crucial role in enhancing the
SNP genotyping Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
SNP genotyping Market Size Analysis, Competitive Insights, Leading Players and G …
SNP genotyping market was valued at approximately USD 31.66 billion, and it is projected to reach around USD 238.25 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 20.1% from 2024 to 2034. SNP genotyping Market Overview The SNP genotyping market is experiencing significant growth, driven by advancements in genotyping technologies, an increase in the prevalence of genetic disorders, and the expansion of pharmacogenomics and precision medicine initiatives. This

All 5 Releases


More Releases for Pneumococcal

Invasive Pneumococcal Disease Market Massive Growth opportunity Ahead
Introduction Invasive pneumococcal disease (IPD), caused by Streptococcus pneumoniae, remains one of the leading causes of serious illness and death worldwide. Manifesting as meningitis, bacteremia, and severe pneumonia, IPD poses the greatest risk to infants, elderly adults, and immunocompromised patients. Despite progress in immunization, the disease continues to cause a significant global burden, particularly in regions with limited vaccine access. The Invasive Pneumococcal Disease Market is entering a transformative phase, fueled by
Key Influencer in the Pneumococcal Vaccine Market 2025: Rising Prevalence Of Pne …
What combination of drivers is leading to accelerated growth in the pneumococcal vaccine market? The escalating occurrence of pneumococcal infections is projected to boost the pneumococcal vaccine market's growth. Pneumococcal infections represent any condition triggered by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This includes illnesses like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine encourages the body to generate antibodies against these bacteria, thereby minimizing or
Pneumococcal Vaccines Market - Preventing Pneumonia: Safeguarding Health with Pn …
Newark, New Castle, USA: The "Pneumococcal Vaccines Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Pneumococcal Vaccines Market: https://www.growthplusreports.com/report/pneumococcal-vaccines-market/7761 This latest report researches the industry structure, sales, revenue,
Global To Invigorate The Intravenous Pneumococcal Vaccines Market
Pneumococcal vaccine is used to prevent infection caused by streptococcus pneumoniae bacteria. There are two types of pneumococcal vaccines: pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. The Centers for Disease Control and Prevention (CDC) recommends pneumococcal conjugate vaccine for all children younger than two years of age, all adults 65 years or older, and for people 2-64 years old with certain medical conditions. The CDC recommends pneumococcal polysaccharide vaccine for all
Pneumococcal Vaccines Market Demands and Gross Margin 2027
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry
Pneumococcal Vaccine Report on Global Pneumococcal Vaccine Market Development, p …
Latest Survey on Pneumococcal Vaccine Market: The Global Pneumococcal Vaccine market report value has been estimated considering the application and regional segments, market share, and size, while the forecast for each product type and application segment has been provided for the global markets. The Pneumococcal Vaccine report offers detailed profiles of the key players to bring out a clear view of the competitive landscape of the Pneumococcal Vaccine Outlook. It also